RT Journal Article
SR Electronic
T1 Longitudinal analyses after COVID-19 recovery or prolonged infection reveal unique immunological signatures after repeated vaccinations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.03.22278353
DO 10.1101/2022.08.03.22278353
A1 Daisuke Hisamatsu
A1 Akari Ikeda
A1 Lisa Ito
A1 Yasushi Matsushita
A1 Makoto Hiki
A1 Hirotake Mori
A1 Yoko Tabe
A1 Toshio Naito
A1 Chihiro Akazawa
YR 2022
UL http://medrxiv.org/content/early/2022/08/03/2022.08.03.22278353.abstract
AB Background To strategically develop preventive and therapeutic measures against coronavirus disease 2019 and its causative virus, SARS-CoV-2, it is critical to fully characterize immune response and sustained immune activation following viral infection and vaccination. However, the mechanisms controlling intrapersonal variation in antibody titers against SARS-CoV-2 antigens remain unclear. To gain further insights into how we can optimize therapeutic and preventive care, we performed a robust molecular and cellular investigation of immune responses in infected, recovered, and vaccinated individuals.Methods We evaluated the expression of 29 cytokines and assessed their correlation with neutralizing potency. We further investigated memory B-cell response in patients infected with the original SARS-CoV-2 strain or other variants of concern, and in vaccinated individuals.Results Correlation analyses showed that the relationship between neutralizing activity and cytokine expression differed according to disease severity and viral strain. Furthermore, long-term longitudinal analyses revealed that post-vaccination neutralizing potential was more strongly associated with various cytokine expression levels in recovered patients than in naïve individuals. Notably, we found a similar distribution of virus-specific antibody gene families in triple-vaccinated individuals and a patient with COVID-19 pneumonia for one year.Conclusion Our results showed that distinct immune responses occur depending on the viral strain suggesting that therapeutic options should be selected on a case-by-case basis. Furthermore, longitudinal analyses revealed biomarker candidates that correlated with repeated vaccination that may be applicable to therapies regulating specific immune responses and novel monoclonal antibodies.Funding This work was supported by the Institutional Funds, YOKOYAMA Foundation for Clinical Pharmacology (#YRY-2121), and the Japan Society for the Promotion of Science (JSPS)/ Ministry of Education, Culture, Sports, Science, and Technology (MEXT) KAKENHI; Grant-in-Aid for Early-Career Scientists (#21K15888).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Otsuka Holdings Co., Ltd., Japan, YOKOYAMA Foundation for Clinical Pharmacology (#YRY-2121), and the Japan Society for the Promotion of Science (JSPS)/The Ministry of Education, Culture, Sports, Science and Technology (MEXT) KAKENHI Grant-in-Aid for Early-Career Scientists (grant number 21K15888).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Juntendo University School of Medicine gave ethical approval for this work (IRB #21-017, #M21-0017).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.